Compare Stocks: APM, CYCN, DARE, and CTXR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
CTXR Citius Pharmaceuticals	$0.57 -4.9%	$0.60	$0.47 ▼ $2.19	$16.42M	1	250,095 shs	222,928 shs
CYCN Cyclerion Therapeutics	$3.49 +3.9%	$21.57	$1.03 ▼ $8.48	$16.33M	1.75	96,117 shs	435,914 shs
DARE Dare Bioscience	$0.81 -5.0%	$1.02	$0.69 ▼ $3.78	$16.72M	1.01	306,178 shs	99,701 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	0.00%	0.00%	-91.79%	-96.18%
CTXR Citius Pharmaceuticals	+3.76%	+6.80%	-0.33%	+4.95%	-48.43%
CYCN Cyclerion Therapeutics	0.00%	0.00%	-87.18%	-84.12%	-83.60%
DARE Dare Bioscience	+4.94%	+16.42%	+3.67%	-59.13%	-58.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
CTXR Citius Pharmaceuticals	$0.57 -4.9%	$0.60	$0.47 ▼ $2.19	$16.42M	1	250,095 shs	222,928 shs
CYCN Cyclerion Therapeutics	$3.49 +3.9%	$21.57	$1.03 ▼ $8.48	$16.33M	1.75	96,117 shs	435,914 shs
DARE Dare Bioscience	$0.81 -5.0%	$1.02	$0.69 ▼ $3.78	$16.72M	1.01	306,178 shs	99,701 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	0.00%	0.00%	-91.79%	-96.18%
CTXR Citius Pharmaceuticals	+3.76%	+6.80%	-0.33%	+4.95%	-48.43%
CYCN Cyclerion Therapeutics	0.00%	0.00%	-87.18%	-84.12%	-83.60%
DARE Dare Bioscience	+4.94%	+16.42%	+3.67%	-59.13%	-58.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	1.00	Sell	N/A	N/A
CTXR Citius Pharmaceuticals	2.40	Hold	$5.00	779.35% Upside
CYCN Cyclerion Therapeutics	1.00	Sell	N/A	N/A
DARE Dare Bioscience	2.33	Hold	$6.50	705.05% Upside

Current Analyst Ratings Breakdown

Latest APM, CYCN, DARE, and CTXR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	CTXR Citius Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/16/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	DARE Dare Bioscience	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1.00
8/25/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	CTXR Citius Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	CYCN Cyclerion Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	9.86	N/A	N/A	$2.17 per share	0.31
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$4.29 per share	N/A
CYCN Cyclerion Therapeutics	$2.07M	7.89	N/A	N/A	$2.31 per share	1.51
DARE Dare Bioscience	$1.03M	15.42	N/A	N/A	$0.20 per share	4.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$1.36M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	-$37.43M	-$1.67	N/A	N/A	N/A	N/A	-59.57%	-34.47%	N/A
CYCN Cyclerion Therapeutics	-$3.53M	-$1.66	N/A	N/A	N/A	-170.11%	-87.96%	-74.86%	11/11/2026 (Estimated)
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	11/12/2026 (Estimated)

Latest APM, CYCN, DARE, and CTXR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q3 2026	CTXR Citius Pharmaceuticals	-$0.36	-$0.34	+$0.02	-$0.34	$5.46 million	N/A
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.78	0.78
CTXR Citius Pharmaceuticals	0.08	0.84	0.40
CYCN Cyclerion Therapeutics	N/A	0.82	0.82
DARE Dare Bioscience	N/A	0.99	0.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
CTXR Citius Pharmaceuticals	16.88%
CYCN Cyclerion Therapeutics	75.62%
DARE Dare Bioscience	6.70%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
CTXR Citius Pharmaceuticals	4.99%
CYCN Cyclerion Therapeutics	34.30%
DARE Dare Bioscience	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	6.35 million	2.29 million	Not Optionable
CTXR Citius Pharmaceuticals	20	27.45 million	26.08 million	Optionable
CYCN Cyclerion Therapeutics	30	4.68 million	3.08 million	No Data
DARE Dare Bioscience	24	19.67 million	18.86 million	Not Optionable

APM, CYCN, DARE, and CTXR Headlines

Recent News About These Companies

Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure

September 14, 2026 | rttnews.com

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

September 14, 2026 | globenewswire.com

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

September 11, 2026 | globenewswire.com

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

August 31, 2026 | globenewswire.com

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

August 27, 2026 | globenewswire.com

Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

August 26, 2026 | markets.businessinsider.com

Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

August 26, 2026 | globenewswire.com

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

August 25, 2026 | globenewswire.com

Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 "50 Over 50: Innovation” List

August 18, 2026 | manilatimes.netM

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

August 18, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)

August 16, 2026 | theglobeandmail.com

Daré Bioscience, Inc.: Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances

August 14, 2026 | finanznachrichten.de

Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

August 14, 2026 | markets.businessinsider.com

Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

August 14, 2026 | globenewswire.com

Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter

August 13, 2026 | seekingalpha.com

Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

August 13, 2026 | markets.businessinsider.com

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2026 | zacks.com

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances

August 13, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, CYCN, DARE, and CTXR Company Descriptions

Aptorum Group NASDAQ:APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Citius Pharmaceuticals NASDAQ:CTXR

$0.57 -0.03 (-4.95%)

Closing price 04:00 PM Eastern

Extended Trading

$0.58 +0.02 (+2.71%)

As of 07:33 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Cyclerion Therapeutics NASDAQ:CYCN

$3.49 +0.13 (+3.87%)

Closing price 09/8/2026

Extended Trading

$3.49 0.00 (0.00%)

As of 09/8/2026 07:42 PM Eastern

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Dare Bioscience NASDAQ:DARE

$0.81 -0.04 (-5.01%)

Closing price 04:00 PM Eastern

Extended Trading

$0.80 -0.01 (-1.41%)

As of 07:58 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, CYCN, DARE, and CTXR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, CYCN, DARE, and CTXR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, CYCN, DARE, and CTXR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, CYCN, DARE, and CTXR Company Descriptions

Aptorum Group NASDAQ:APM

Citius Pharmaceuticals NASDAQ:CTXR

Cyclerion Therapeutics NASDAQ:CYCN

Dare Bioscience NASDAQ:DARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, CYCN, DARE, and CTXR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, CYCN, DARE, and CTXR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, CYCN, DARE, and CTXR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, CYCN, DARE, and CTXR Company Descriptions

Aptorum Group NASDAQ:APM

Citius Pharmaceuticals NASDAQ:CTXR

Cyclerion Therapeutics NASDAQ:CYCN

Dare Bioscience NASDAQ:DARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools